Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records
Reference
Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1 November 1982 - 5 December 1982
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Reliability 2 is assigned because the study conducted similar to OECD TG 406 (GPMT), without GLP and with minor deviations that do not influence the quality of the results.
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 406 (Skin Sensitisation)
Deviations:
no
GLP compliance:
not specified
Type of study:
guinea pig maximisation test
Species:
guinea pig
Strain:
Dunkin-Hartley
Sex:
male
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: D. Hall, Newchurch, Staffordshire
- Age at acclimatization start: 4-6 weeks
- Weight at acclimatization start: 310-417 g
- Housing: suspended cages with wire mesh floors
- Diet: free access to Vitamin C-enriched guinea pig diet (Special Diets Services Limited)
- Water: free access to tap water
- Acclimation period: one week

ENVIRONMENTAL CONDITIONS (check details)
- Temperature (°C): +/- 21
- Humidity (%): 30-70
- Air changes (per hr): +/- 15
- Photoperiod (hrs dark / hrs light): 12/12
Route:
intradermal and epicutaneous
Vehicle:
paraffin oil
Concentration / amount:
- 5% (v/v) for the intradermal induction
- Undiluted (100%) for the epidermal induction
- 1%, 5%, 10% and 20% (v/v) for the challenge
Route:
epicutaneous, occlusive
Vehicle:
paraffin oil
Concentration / amount:
- 5% (v/v) for the intradermal induction
- Undiluted (100%) for the epidermal induction
- 1%, 5%, 10% and 20% (v/v) for the challenge
No. of animals per dose:
Test animals: 15
Control animals: 15
Details on study design:
RANGE FINDING TESTS
Intradermal and topical irritancy of a range of dilutions of the test substance in liquid paraffin was investigated to identify irritant test substance concentrations suitable for the induction phase of the main study. A range of non-irritant concentrations was selected for the challenge phase following consultation with the Sponsor.

MAIN STUDY
A. INDUCTION EXPOSURE
1) Intradermal injections
- Concentration: 5%
- Site: the dorsal scapular region (clipped free of hair)

Test group (three pairs of 0.1 mL intradermal injections):
1) Freund's complete adjuvant (FCA) 50:50 with water
2) Test substance at 5% (v/v) in vehicle
3) Test substance at 5% (v/v) in a 50:50 mixture of FCA with vehicle

Control group (three pairs of 0.1 mL intradermal injections):
1) Freund's complete adjuvant (FCA) 50:50 with water
2) Vehicle
3) 50:50 mixture of FCA with vehicle

2) Topical applications one week after the injections:
- Site: the dorsal scapular region (clipped and shaved free of hair)
- Concentration: test animals undiluted test article (100%), control animals no data (page missing in report)
- Amount: saturated patch
- Area: 8 cm2
- Exposure period: 48 hours (occlusive)

B. CHALLENGE EXPOSURE (control and test group)
- Concentrations: 1%, 5%, 10% and 20%
- Evaluation: 24, 48 and 72 hours after start of challenge
- Other information on challenge exposure: no data (page missing in report)
Positive control substance(s):
no
Reading:
other: 24, 48 and 72 hours after challenge
Group:
negative control
Dose level:
1%
No. with + reactions:
0
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: negative control. Dose level: 1%. No with. + reactions: 0.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
negative control
Dose level:
5%
No. with + reactions:
0
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: negative control. Dose level: 5%. No with. + reactions: 0.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
negative control
Dose level:
10%
No. with + reactions:
0
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: negative control. Dose level: 10%. No with. + reactions: 0.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
negative control
Dose level:
20%
No. with + reactions:
0
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: negative control. Dose level: 20%. No with. + reactions: 0.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
test chemical
Dose level:
1%
No. with + reactions:
0
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: test group. Dose level: 1%. No with. + reactions: 0.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
test chemical
Dose level:
5%
No. with + reactions:
8
Total no. in group:
15
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: test group. Dose level: 5%. No with. + reactions: 8.0. Total no. in groups: 15.0.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
test chemical
Dose level:
10%
No. with + reactions:
7
Total no. in group:
15
Clinical observations:
Result in one animal was inconclusive
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: test group. Dose level: 10%. No with. + reactions: 7.0. Total no. in groups: 15.0. Clinical observations: Result in one animal was inconclusive.
Reading:
other: 24, 48 and 72 hours after challenge
Group:
test chemical
Dose level:
20%
No. with + reactions:
12
Total no. in group:
14
Clinical observations:
Result in one animal was inconclusive, one animal was excluded
Remarks on result:
other: Reading: other: 24, 48 and 72 hours after challenge. Group: test group. Dose level: 20%. No with. + reactions: 12.0. Total no. in groups: 14.0. Clinical observations: Result in one animal was inconclusive, one animal was excluded.

Results of the three readings (24, 48 and 72 hours after start of challenge) are summarized per challenge concentration. From one guinea-pig the patch was lost during the 4th challenge (20% test substance) application. No scores were therefore recorded for this animal on this occasion.

Interpretation of results:
sensitising
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
Under the conditions of this study, performed in accordance with a method similar to OECD 406, it was observed that skin sensitisation occurred in >30% of the test animals at tested concentrations at and above 5%, but not at 1%. Based on these results, the test substance can be considered a skin sensitiser.
Executive summary:

The skin sensitisation potential of the substance was investigated by performing a guinea pig maximisation test performed in accordance with a method similar to OECD 406 (GPMT), but there is no indication of GLP compliance. A concentration of 5% was used for the intradermal induction, 100% (undiluted test article) for the epidermal induction and 1%, 5%, 10% and 20% for the challenge. In the 1% test group none of the fifteen animals showed a sensitisation response. In the groups exposed to 5%, 10% and 20% of the test sample, 8/15 animals (53%), 7/15 animals (47%) and 8/14 animals (86%) showed a positive response, respectively. Based on these results the substance is considered to be a skin sensitiser as >30% of the animals showed sensitisation at these concentrations.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:
Migrated from Short description of key information:
The skin sensitisation potential of the substance was investigated by performing a guinea pig maximisation test performed in accordance with a method similar to OECD 406, but there is no indication of GLP compliance. A concentration of 5% was used for the intradermal induction, 100% (undiluted test article) for the epidermal induction and 1%, 5%, 10% and 20% for the challenge. In the 1% test group none of the fifteen animals showed a sensitisation response. In the groups exposed to 5%, 10% and 20% of the test sample, 8/15 animals (53%), 7/15 animals (47%) and 8/14 animals (86%) showed a positive response, respectively. Based on these results the substance is considered to be a skin sensitiser as >30% of the animals showed sensitisation at these concentrations.

Justification for selection of skin sensitisation endpoint:
The result of this study is sufficiently reliable and sufficiently adequate for covering this endpoint.

Justification for classification or non-classification

According to the criteria outlined in Annex VI of 67/548/EEC (DSD) and Annex I of 1272/2008/EC (CLP), the substance needs to be classified as a skin sensitizer (Skin Sens. 1B, H317) as at an intradermal induction concentration of 5% (the highest concentration tested) more than 30% response were seen at the challenge phase.